| Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. | |
| | |
MedLine Citation:
|
PMID: 21606347 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate cancer (CRPC), responses are variable and short-lived. There is an urgent need to understand the basis of resistance to optimize their future use. We reasoned that a radiopharmaceutical that measures intratumoral changes in AR signaling could substantially improve our understanding of AR pathway directed therapies. Expanding on previous observations, we first show that prostate-specific membrane antigen (PSMA) is repressed by androgen treatment in multiple models of AR-positive prostate cancer in an AR-dependent manner. Conversely, antiandrogens up-regulate PSMA expression. These expression changes, including increased PSMA expression in response to treatment with the antiandrogen MDV3100, can be quantitatively measured in vivo in human prostate cancer xenograft models through PET imaging with a fully humanized, radiolabeled antibody to PSMA, (64)Cu-J591. Collectively, these results establish that relative changes in PSMA expression levels can be quantitatively measured using a human-ready imaging reagent and could serve as a biomarker of AR signaling to noninvasively evaluate AR activity in patients with CRPC. |
| | |
Authors:
|
Michael J Evans; Peter M Smith-Jones; John Wongvipat; Vincent Navarro; Sae Kim; Neil H Bander; Steven M Larson; Charles L Sawyers |
Related Documents
:
|
21610217 - Between-method differences in prostate-specific antigen assays affect prostate cancer r... 12717837 - Hogg1 ser326cys polymorphism modifies the significance of the environmental risk factor... 1212647 - The control of large bowel cancers. present status and it challenges. 21772887 - Association of catechol-o-methyl transferase gene polymorphism with prostate cancer and... 11790987 - Molecular alterations in ductal carcinoma in situ of the breast. 20172727 - A vision to optimise the management of primary breast cancer in older women. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-5-23 |
Journal Detail:
|
Title: Proceedings of the National Academy of Sciences of the United States of America Volume: - ISSN: 1091-6490 ISO Abbreviation: - Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-5-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7505876 Medline TA: Proc Natl Acad Sci U S A Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Human Oncology and Pathogenesis Program, Department of Radiology, Division of Urology, Molecular Pharmacology and Chemistry, Nuclear Medicine Service, and Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ a...
Next Document: PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function.